Biotech Values

[oc631]

VRUS tested PSI-938 for 2 weeks of monotherapy in the NUCLEAR study with GT1 patients. Going out 12 weeks with PSI-7977 monotherapy in GT2/GT3 does indicate an open mind at the FDA and you make a valid point. Phase 3 studies with Interferon/Riba might be pointless come November if we see continued positive results and the FDA remains open minded.